Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review
In recent years, a growing interest has been directed towards oligometastatic prostate cancer (OMPC), as patients with three to five metastatic lesions have shown a significantly better survival as compared with those harboring a higher number of lesions. The efficacy of local ablative treatments di...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/13/3278 |
| _version_ | 1797411269334007808 |
|---|---|
| author | Giulia Corrao Mattia Zaffaroni Luca Bergamaschi Matteo Augugliaro Stefania Volpe Matteo Pepa Giuseppina Bonizzi Salvatore Pece Nicola Amodio Francesco Alessandro Mistretta Stefano Luzzago Gennaro Musi Sarah Alessi Francesco Maria La Fauci Chiara Tordonato Daniela Tosoni Federica Cattani Sara Gandini Giuseppe Petralia Gabriella Pravettoni Ottavio De Cobelli Giuseppe Viale Roberto Orecchia Giulia Marvaso Barbara Alicja Jereczek-Fossa |
| author_facet | Giulia Corrao Mattia Zaffaroni Luca Bergamaschi Matteo Augugliaro Stefania Volpe Matteo Pepa Giuseppina Bonizzi Salvatore Pece Nicola Amodio Francesco Alessandro Mistretta Stefano Luzzago Gennaro Musi Sarah Alessi Francesco Maria La Fauci Chiara Tordonato Daniela Tosoni Federica Cattani Sara Gandini Giuseppe Petralia Gabriella Pravettoni Ottavio De Cobelli Giuseppe Viale Roberto Orecchia Giulia Marvaso Barbara Alicja Jereczek-Fossa |
| author_sort | Giulia Corrao |
| collection | DOAJ |
| description | In recent years, a growing interest has been directed towards oligometastatic prostate cancer (OMPC), as patients with three to five metastatic lesions have shown a significantly better survival as compared with those harboring a higher number of lesions. The efficacy of local ablative treatments directed on metastatic lesions (metastases-directed treatments) was extensively investigated, with the aim of preventing further disease progression and delaying the start of systemic androgen deprivation therapies. Definitive diagnosis of prostate cancer is traditionally based on histopathological analysis. Nevertheless, a bioptic sample—static in nature—inevitably fails to reflect the dynamics of the tumor and its biological response due to the dynamic selective pressure of cancer therapies, which can profoundly influence spatio-temporal heterogeneity. Furthermore, even with new imaging technologies allowing an increasingly early detection, the diagnosis of oligometastasis is currently based exclusively on radiological investigations. Given these premises, the development of minimally-invasive liquid biopsies was recently promoted and implemented as predictive biomarkers both for clinical decision-making at pre-treatment (baseline assessment) and for monitoring treatment response during the clinical course of the disease. Through liquid biopsy, different biomarkers, commonly extracted from blood, urine or saliva, can be characterized and implemented in clinical routine to select targeted therapies and assess treatment response. Moreover, this approach has the potential to act as a tissue substitute and to accelerate the identification of novel and consistent predictive analytes cost-efficiently. However, the utility of tumor profiling is currently limited in OMPC due to the lack of clinically validated predictive biomarkers. In this scenario, different ongoing trials, such as the RADIOSA trial, might provide additional insights into the biology of the oligometastatic state and on the identification of novel biomarkers for the outlining of true oligometastatic patients, paving the way towards a wider ideal approach of personalized medicine. The aim of the present narrative review is to report the current state of the art on the solidity of liquid biopsy-related analytes such as CTCs, cfDNA, miRNA and epi-miRNA, and to provide a benchmark for their further clinical implementation. Arguably, this kind of molecular profiling could refine current developments in the era of precision oncology and lead to more refined therapeutic strategies in this subset of oligometastatic patients. |
| first_indexed | 2024-03-09T04:43:37Z |
| format | Article |
| id | doaj.art-1494755d95614d459fa477eba6913d7f |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T04:43:37Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-1494755d95614d459fa477eba6913d7f2023-12-03T13:18:14ZengMDPI AGCancers2072-66942021-06-011313327810.3390/cancers13133278Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative ReviewGiulia Corrao0Mattia Zaffaroni1Luca Bergamaschi2Matteo Augugliaro3Stefania Volpe4Matteo Pepa5Giuseppina Bonizzi6Salvatore Pece7Nicola Amodio8Francesco Alessandro Mistretta9Stefano Luzzago10Gennaro Musi11Sarah Alessi12Francesco Maria La Fauci13Chiara Tordonato14Daniela Tosoni15Federica Cattani16Sara Gandini17Giuseppe Petralia18Gabriella Pravettoni19Ottavio De Cobelli20Giuseppe Viale21Roberto Orecchia22Giulia Marvaso23Barbara Alicja Jereczek-Fossa24Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, ItalyDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, ItalyDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, ItalyDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, ItalyDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, ItalyDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, ItalyDepartment of Pathology, IEO, European Institute of Oncology IRCCS, 20141 Milan, ItalyDepartment of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, ItalyDepartment of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, ItalyDepartment of Urology, IEO, European Institute of Oncology IRCCS, 20141 Milan, ItalyDepartment of Urology, IEO, European Institute of Oncology IRCCS, 20141 Milan, ItalyDepartment of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, ItalyDivision of Radiology, IEO, European Institute of Oncology IRCCS, 20141 Milan, ItalyUnit of Medical Physics IEO, European Institute of Oncology IRCCS, 20141 Milan, ItalyDepartment of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, ItalyNovel Diagnostics Program, IEO, European Institute of Oncology IRCCS, 20141 Milan, ItalyUnit of Medical Physics IEO, European Institute of Oncology IRCCS, 20141 Milan, ItalyDepartment of Experimental Oncology, IEO, European Institute of Oncology IRCCS, 20141 Milan, ItalyDepartment of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, ItalyDepartment of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, ItalyDepartment of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, ItalyDepartment of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, ItalyScientific Direction, IEO, European Institute of Oncology IRCCS, 20141 Milan, ItalyDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, ItalyDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, ItalyIn recent years, a growing interest has been directed towards oligometastatic prostate cancer (OMPC), as patients with three to five metastatic lesions have shown a significantly better survival as compared with those harboring a higher number of lesions. The efficacy of local ablative treatments directed on metastatic lesions (metastases-directed treatments) was extensively investigated, with the aim of preventing further disease progression and delaying the start of systemic androgen deprivation therapies. Definitive diagnosis of prostate cancer is traditionally based on histopathological analysis. Nevertheless, a bioptic sample—static in nature—inevitably fails to reflect the dynamics of the tumor and its biological response due to the dynamic selective pressure of cancer therapies, which can profoundly influence spatio-temporal heterogeneity. Furthermore, even with new imaging technologies allowing an increasingly early detection, the diagnosis of oligometastasis is currently based exclusively on radiological investigations. Given these premises, the development of minimally-invasive liquid biopsies was recently promoted and implemented as predictive biomarkers both for clinical decision-making at pre-treatment (baseline assessment) and for monitoring treatment response during the clinical course of the disease. Through liquid biopsy, different biomarkers, commonly extracted from blood, urine or saliva, can be characterized and implemented in clinical routine to select targeted therapies and assess treatment response. Moreover, this approach has the potential to act as a tissue substitute and to accelerate the identification of novel and consistent predictive analytes cost-efficiently. However, the utility of tumor profiling is currently limited in OMPC due to the lack of clinically validated predictive biomarkers. In this scenario, different ongoing trials, such as the RADIOSA trial, might provide additional insights into the biology of the oligometastatic state and on the identification of novel biomarkers for the outlining of true oligometastatic patients, paving the way towards a wider ideal approach of personalized medicine. The aim of the present narrative review is to report the current state of the art on the solidity of liquid biopsy-related analytes such as CTCs, cfDNA, miRNA and epi-miRNA, and to provide a benchmark for their further clinical implementation. Arguably, this kind of molecular profiling could refine current developments in the era of precision oncology and lead to more refined therapeutic strategies in this subset of oligometastatic patients.https://www.mdpi.com/2072-6694/13/13/3278oligometastatic prostate cancerbiomarkermiRNACTCepi-miRNA |
| spellingShingle | Giulia Corrao Mattia Zaffaroni Luca Bergamaschi Matteo Augugliaro Stefania Volpe Matteo Pepa Giuseppina Bonizzi Salvatore Pece Nicola Amodio Francesco Alessandro Mistretta Stefano Luzzago Gennaro Musi Sarah Alessi Francesco Maria La Fauci Chiara Tordonato Daniela Tosoni Federica Cattani Sara Gandini Giuseppe Petralia Gabriella Pravettoni Ottavio De Cobelli Giuseppe Viale Roberto Orecchia Giulia Marvaso Barbara Alicja Jereczek-Fossa Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review Cancers oligometastatic prostate cancer biomarker miRNA CTC epi-miRNA |
| title | Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review |
| title_full | Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review |
| title_fullStr | Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review |
| title_full_unstemmed | Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review |
| title_short | Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review |
| title_sort | exploring mirna signature and other potential biomarkers for oligometastatic prostate cancer characterization the biological challenge behind clinical practice a narrative review |
| topic | oligometastatic prostate cancer biomarker miRNA CTC epi-miRNA |
| url | https://www.mdpi.com/2072-6694/13/13/3278 |
| work_keys_str_mv | AT giuliacorrao exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT mattiazaffaroni exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT lucabergamaschi exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT matteoaugugliaro exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT stefaniavolpe exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT matteopepa exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT giuseppinabonizzi exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT salvatorepece exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT nicolaamodio exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT francescoalessandromistretta exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT stefanoluzzago exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT gennaromusi exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT sarahalessi exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT francescomarialafauci exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT chiaratordonato exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT danielatosoni exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT federicacattani exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT saragandini exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT giuseppepetralia exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT gabriellapravettoni exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT ottaviodecobelli exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT giuseppeviale exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT robertoorecchia exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT giuliamarvaso exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview AT barbaraalicjajereczekfossa exploringmirnasignatureandotherpotentialbiomarkersforoligometastaticprostatecancercharacterizationthebiologicalchallengebehindclinicalpracticeanarrativereview |